These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36811990)

  • 1. Health care costs associated with unrecognized progression to late-stage kidney disease.
    Spencer D; Dunning S; McPheeters J; St Clair Russell J; Hane C
    Am J Manag Care; 2023 Feb; 29(2):e64-e68. PubMed ID: 36811990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.
    Black C; Sharma P; Scotland G; McCullough K; McGurn D; Robertson L; Fluck N; MacLeod A; McNamee P; Prescott G; Smith C
    Health Technol Assess; 2010 Apr; 14(21):1-184. PubMed ID: 20441712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. All-cause costs increase exponentially with increased chronic kidney disease stage.
    Golestaneh L; Alvarez PJ; Reaven NL; Funk SE; McGaughey KJ; Romero A; Brenner MS; Onuigbo M
    Am J Manag Care; 2017 Jun; 23(10 Suppl):S163-S172. PubMed ID: 28978205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stage.
    Gagnon-Sanschagrin P; Liang Y; Sanon M; Oberdhan D; Guérin A; Cloutier M
    J Med Econ; 2021; 24(1):193-201. PubMed ID: 33464936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?
    Kent S; Schlackow I; Lozano-Kühne J; Reith C; Emberson J; Haynes R; Gray A; Cass A; Baigent C; Landray MJ; Herrington W; Mihaylova B;
    BMC Nephrol; 2015 Apr; 16():65. PubMed ID: 25924679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Prescription Analgesic Use in Older Adults With and Without Chronic Kidney Disease and Outcomes.
    Han Y; Balkrishnan R; Hirth RA; Hutton DW; He K; Steffick DE; Saran R
    JAMA Netw Open; 2020 Sep; 3(9):e2016839. PubMed ID: 32997126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of health literacy profile of patients with end-stage kidney disease on dialysis versus non-dialysis chronic kidney disease and the influencing factors: a cross-sectional study.
    Murali K; Mullan J; Roodenrys S; Lonergan M
    BMJ Open; 2020 Oct; 10(10):e041404. PubMed ID: 33122326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying chronic kidney disease stage 3 with excess disease burden.
    Campbell A; Chu L; Crittenden S; Sutton A; Boehler A
    Am J Manag Care; 2024 Jun; 30(6):e172-e177. PubMed ID: 38912931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CKD Progression in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation Treated With Apixaban Versus Warfarin.
    Wetmore JB; Yan H; Herzog CA; Weinhandl E; Reyes JL; Roetker NS
    Am J Kidney Dis; 2021 Aug; 78(2):180-189. PubMed ID: 33421454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression to end-stage kidney disease in Japanese children with chronic kidney disease: results of a nationwide prospective cohort study.
    Ishikura K; Uemura O; Hamasaki Y; Ito S; Wada N; Hattori M; Ohashi Y; Tanaka R; Nakanishi K; Kaneko T; Honda M; ;
    Nephrol Dial Transplant; 2014 Apr; 29(4):878-84. PubMed ID: 24516225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disparities in Chronic Kidney Disease Progression by Medicare Advantage Enrollees.
    Diamantidis CJ; Zepel L; Wang V; Smith VA; Hudson Scholle S; Tamayo L; Maciejewski ML
    Am J Nephrol; 2021; 52(12):949-957. PubMed ID: 34875668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease.
    Smart NA; Dieberg G; Ladhani M; Titus T
    Cochrane Database Syst Rev; 2014 Jun; (6):CD007333. PubMed ID: 24938824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-related difference in health care use and costs of patients with chronic kidney disease and matched controls: analysis of Dutch health care claims data.
    van Oosten MJM; Logtenberg SJJ; Leegte MJH; Bilo HJG; Mohnen SM; Hakkaart-van Roijen L; Hemmelder MH; de Wit GA; Jager KJ; Stel VS
    Nephrol Dial Transplant; 2020 Dec; 35(12):2138-2146. PubMed ID: 31598728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urologic care and progression to end-stage kidney disease: a Chronic Kidney Disease in Children (CKiD) nested case-control study.
    Chu DI; Abraham AG; Tasian GE; Denburg MR; Ross ME; Zderic SA; Furth SL
    J Pediatr Urol; 2019 May; 15(3):266.e1-266.e7. PubMed ID: 30962011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmented Nurse Care Management in CKD Stages 4 to 5: A Randomized Trial.
    Fishbane S; Agoritsas S; Bellucci A; Halinski C; Shah HH; Sakhiya V; Balsam L
    Am J Kidney Dis; 2017 Oct; 70(4):498-505. PubMed ID: 28396108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer Risk and Mortality in Patients With Kidney Disease: A Population-Based Cohort Study.
    Kitchlu A; Reid J; Jeyakumar N; Dixon SN; Munoz AM; Silver SA; Booth CM; Chan CTM; Garg AX; Amir E; Kim SJ; Wald R
    Am J Kidney Dis; 2022 Oct; 80(4):436-448.e1. PubMed ID: 35405208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study.
    Koye DN; Magliano DJ; Reid CM; Jepson C; Feldman HI; Herman WH; Shaw JE
    Am J Kidney Dis; 2018 Nov; 72(5):653-661. PubMed ID: 29784612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical costs of CKD in the Medicare population.
    Honeycutt AA; Segel JE; Zhuo X; Hoerger TJ; Imai K; Williams D
    J Am Soc Nephrol; 2013 Sep; 24(9):1478-83. PubMed ID: 23907508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Renal Disease on Patients with Hepatitis C: A Retrospective Analysis of Disease Burden, Clinical Outcomes, and Health Care Utilization and Cost.
    Solid CA; Peter SA; Natwick T; Guo H; Collins AJ; Arduino JM
    Nephron; 2017; 136(2):54-61. PubMed ID: 28214902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.